Localized Renal Cell Carcinoma: Surgical & Non-Surgical Approaches

How to cite: Daneshvar MA. Localized renal cell carcinoma: surgical & non-surgical approaches. Grand Rounds in Urology. November 2025. Accessed February 2026. https://grandroundsinurology.com/localized-renal-cell-carcinoma-surgical-non-surgical-approaches/

Summary

Michael A. Daneshvar, MD, MS, Assistant Professor of Clinical Urology and Urologic Oncology, Division Chief of Urologic Oncology: APD, Urology Residency, University of California, Irvine, Irvine, California, provides a comprehensive review of contemporary management strategies for localized renal cell carcinoma, integrating surgical, ablative, radiation, and surveillance approaches within a risk-stratified and precision-driven framework. Dr. Daneshvar reviews epidemiology, histologic subtypes, hereditary considerations, and evolving tools that inform individualized treatment decisions.

He begins with the rising incidence of small renal masses, largely attributed to increased cross-sectional imaging, and emphasizes that most renal cell carcinomas are sporadic, with a meaningful minority driven by hereditary syndromes. Histologic subtypes are reviewed, including clear cell, papillary, chromophobe, oncocytoma, and collecting duct carcinoma, with management implications outlined for each.

Surgical management is considered the cornerstone of treatment for localized disease. Partial nephrectomy is emphasized as the preferred approach for T1 tumors, prioritizing nephron preservation while maintaining excellent oncologic outcomes. Performance metrics, including negative surgical margins, minimized ischemia time, and preserved renal function, are discussed. Dr. Daneshvar points out that radical nephrectomy is reserved for larger or anatomically complex tumors when nephron-sparing surgery is not feasible, with a focus on long-term renal and cardiovascular consequences.

Dr. Daneshvar reviews non-surgical treatment options, including cryoablation and microwave ablation, as well as active surveillance when appropriate. Emerging data on stereotactic body radiation therapy are presented as an option for some patients, with evidence still maturing.

Dr. Daneshvar highlights precision tools that guide decision-making, including nephrometry scoring systems, molecular imaging using girentuximab positron emission tomography (PET), and genomic classifiers. He shares case examples that illustrate practical applications across diverse clinical scenarios.

Dr. Daneshvar emphasizes a personalized treatment plan that considers risk stratification, hereditary factors, and kidney preservation.

About the 32nd Annual Perspectives in Urology: Point Counterpoint conference: Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, this conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking.